Metastatic Breast Cancer/LinkedIn
Jul 27, 2024, 14:49
Identification of Resistance Biomarkers to HER2 Inhibitors
Iván González, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X about a paper titled “Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer” published in MDPI.
Authors: Alvan Cai, Yuan Chen, Lily S. Wang, John K. Cusick and Yihui Shi.
“Identification of Resistance Biomarkers to HER2 Inhibitors: Advances and Challenges in HER2+ Breast Cancer.
- Therapeutic advances: HER2 inhibitors have significantly improved the treatment of HER2+ breast cancer.
- Persistent challenge: Resistance to these drugs remains a critical issue.
- Key biomarkers identified: Mutations in the ERBB2 gene, activation of alternative signaling pathways, expression of estrogen receptors, and alterations in regulatory protein levels have been found.
- New explorations: More effective regimens and promising combination therapies are being investigated.
This review highlights current HER2-targeted therapies, analyzes predictive biomarkers of drug resistance, and presents emerging therapies, especially combination treatments, aimed at overcoming resistance in the context of HER2+ breast cancer.”
Source: Iván González/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19